|
Gene: S100PBP |
Gene summary for S100PBP |
Gene summary. |
Gene information | Species | Human | Gene symbol | S100PBP | Gene ID | 64766 |
Gene name | S100P binding protein | |
Gene Alias | S100PBPR | |
Cytomap | 1p35.1 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A0S2Z5M0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64766 | S100PBP | LZE4T | Human | Esophagus | ESCC | 1.14e-08 | 2.79e-01 | 0.0811 |
64766 | S100PBP | LZE7T | Human | Esophagus | ESCC | 6.53e-05 | 4.68e-01 | 0.0667 |
64766 | S100PBP | LZE20T | Human | Esophagus | ESCC | 4.58e-05 | 1.91e-01 | 0.0662 |
64766 | S100PBP | LZE24T | Human | Esophagus | ESCC | 1.50e-13 | 3.88e-01 | 0.0596 |
64766 | S100PBP | LZE6T | Human | Esophagus | ESCC | 7.74e-03 | 2.72e-01 | 0.0845 |
64766 | S100PBP | P1T-E | Human | Esophagus | ESCC | 1.01e-09 | 3.60e-01 | 0.0875 |
64766 | S100PBP | P2T-E | Human | Esophagus | ESCC | 1.02e-15 | 3.21e-01 | 0.1177 |
64766 | S100PBP | P4T-E | Human | Esophagus | ESCC | 1.37e-06 | 1.64e-01 | 0.1323 |
64766 | S100PBP | P5T-E | Human | Esophagus | ESCC | 6.69e-16 | 3.12e-01 | 0.1327 |
64766 | S100PBP | P8T-E | Human | Esophagus | ESCC | 1.30e-15 | 2.16e-01 | 0.0889 |
64766 | S100PBP | P9T-E | Human | Esophagus | ESCC | 4.03e-04 | 1.17e-01 | 0.1131 |
64766 | S100PBP | P10T-E | Human | Esophagus | ESCC | 3.16e-13 | 2.91e-01 | 0.116 |
64766 | S100PBP | P11T-E | Human | Esophagus | ESCC | 3.62e-03 | 2.42e-01 | 0.1426 |
64766 | S100PBP | P12T-E | Human | Esophagus | ESCC | 7.57e-09 | 2.03e-01 | 0.1122 |
64766 | S100PBP | P15T-E | Human | Esophagus | ESCC | 2.68e-08 | 2.46e-01 | 0.1149 |
64766 | S100PBP | P16T-E | Human | Esophagus | ESCC | 1.34e-10 | 1.80e-01 | 0.1153 |
64766 | S100PBP | P17T-E | Human | Esophagus | ESCC | 8.01e-03 | 1.35e-01 | 0.1278 |
64766 | S100PBP | P19T-E | Human | Esophagus | ESCC | 2.77e-02 | 2.11e-01 | 0.1662 |
64766 | S100PBP | P20T-E | Human | Esophagus | ESCC | 5.60e-11 | 2.86e-01 | 0.1124 |
64766 | S100PBP | P21T-E | Human | Esophagus | ESCC | 2.99e-19 | 3.85e-01 | 0.1617 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
S100PBP | SNV | Missense_Mutation | novel | c.496G>C | p.Asp166His | p.D166H | Q96BU1 | protein_coding | deleterious(0.01) | possibly_damaging(0.847) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
S100PBP | insertion | Frame_Shift_Ins | novel | c.812_813insACAGAGGAAGAGA | p.Ser272GlnfsTer15 | p.S272Qfs*15 | Q96BU1 | protein_coding | TCGA-AO-A0JJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophospamide | SD | ||
S100PBP | SNV | Missense_Mutation | c.915N>C | p.Lys305Asn | p.K305N | Q96BU1 | protein_coding | deleterious(0) | possibly_damaging(0.714) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
S100PBP | SNV | Missense_Mutation | novel | c.647A>G | p.Asn216Ser | p.N216S | Q96BU1 | protein_coding | tolerated(0.21) | benign(0.037) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
S100PBP | SNV | Missense_Mutation | c.301T>G | p.Ser101Ala | p.S101A | Q96BU1 | protein_coding | tolerated(0.11) | benign(0.01) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
S100PBP | SNV | Missense_Mutation | c.350N>A | p.Pro117His | p.P117H | Q96BU1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
S100PBP | SNV | Missense_Mutation | rs749717746 | c.13C>T | p.Arg5Trp | p.R5W | Q96BU1 | protein_coding | deleterious_low_confidence(0) | benign(0.409) | TCGA-AY-6196-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
S100PBP | SNV | Missense_Mutation | novel | c.297N>G | p.Asn99Lys | p.N99K | Q96BU1 | protein_coding | deleterious(0.04) | benign(0.058) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
S100PBP | SNV | Missense_Mutation | novel | c.413N>C | p.Val138Ala | p.V138A | Q96BU1 | protein_coding | tolerated(1) | benign(0.001) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
S100PBP | SNV | Missense_Mutation | novel | c.64N>A | p.Ala22Thr | p.A22T | Q96BU1 | protein_coding | tolerated(0.11) | benign(0.254) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |